The Evaluation Effects of Estrogen on Dlgap5 and Angpt-2 Genes Expression in Prostate Cancer-3 (Pc3) Cell Lines

Background and aim: benign prostatic hyperplasia (bph) and prostate cancer are common clinical complications in urology. recent studies have demonstrated that estrogen receptor signaling pathways may be important in the development and maintenance of bph and prostate cancer. estrogen and selective estrogen receptor modulators (serms) have shown a potential role in promoting or inhibiting prostate proliferation in bph and prostate cancer. the aim of this study is to investigate the effect of estrogen on dlgap5 and angpt-2 genes expressions in prostate cancer-3 (pc3) cell lines.methods: in this study, prostate cancer cells of the pc3 cell line were cultured in dmem medium with 10% bovine serum. cells were treated at 24, 48 and 72 hours intervals. the cells were exposed to concentrations of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 nµ of estrogen hormone and the cell growth was measured by mtt colorimetric method.results: by increasing the concentration of estrogen hormone, and time-dependently, while increasing the induction of apoptosis, the bioavailability of the cells and the expression level of angpt-2 and dlgap5 genes decreased. the maximum effect was gained by 100 nµ of estrogen hormone and 72 hours after treatment of the cells.conclusion: estrogen hormone, in a dose-dependent and time-dependent manner, decreases cell growth, increases induction of apoptosis and reduces the expression of these genes examined in pc3 cells. according to the current evidence, estrogen hormone can act as an anti-cancer agent.